Drug Approval | July 26, 2024
Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Subscribe To Our Newsletter & Stay Updated
